East Coast Population Analysis Group
The East Coast Population Analysis Group is a forum for pharmacometricians, scientists, and researchers with an interest in modeling and population approaches to the analysis of PK/PD data, from the US East Coast region and beyond.
The ECPAG conference provides scientists and students of Pharmacometrics alike an informal forum for the presentation and discussion of their work in the application of population PK/PD modeling and simulation in pharmaceutical and drug development research, as well as the regulatory and clinical implications.
Presentations from prior ECPAG Conferences are available for downlaod in PDF format.
2006 Workshop Presentations
- Ludden: "In Fond Memory of Professor Stuart L. Beal - June, 1941 ï¿½ January, 2006"
- Grasela: "Engineering the Pharmacometrics Enterprise"
- Gastonguay: "Acknowledging and Incorporating Uncertainty in Model-Based Inferences"
- Mould: "Limitations of Commonly Used Diagnostic Plots and Value of The Predictive Check for Model Development"
- Fiedler-Kelly: "Pharmacometric Analysis Plans & Technical Reports"
- Gobburu: "Regulatory Perspective on the Use of Pharmacometric Knowledge in Regulatory Review: Application of Quantitative Tools: Where is FDA Going?"
- Grasela: "Learning from Doing: A Workshop on Pharmacometric Heuristics"
2006 Scientific Meeting Presentations
- Ludden: "NONMEM VI New Features"
- Michels: "The Use of Collinearity Diagnostics in PK Model Building"
- Guzy: "The Monte-Carlo Parametric Expectation Maximization Algorithm"
- Sale: "Parallel NONMEM, Initial experience"
- Devarakonda: "Population Pharmacokinetics of Theophylline in South Indian Patients"
- Heathman: "Incorporating Uncertainty and Variability into Various Types of Simulation: Implementation and Application"
- Cirincione: "The Role of Requirements in Model-Based Decision Making"
- Wang: "The Importance of Early Interaction with FDA: EOP2A Experiences"
2004 Workshop Presentations
Session 1: Model Qualification
- Fiedler-Kelly: Introduction to Workshop: Session I Content and Terms
- Gastonguay: Brief Overview of Model Qualification and Validation Methodologies
- Case Study 1: PopPK Analysis of a High-Dose Antineoplastic for Bone Marrow Transplant in Adults and Children
- Case Study 2: PopPK Analysis of an Intravenous Dose Ranging Study Evaluating an Antineoplastic Agent in Adults and Children
- Case Study 3: Drug X PK-PD Modeling/Simulation
- Case Study 4: Model Qualifications in Industrial Applications
- Duffull: Selecting The Right Model Across Modeling Platforms ï¿½ A Pop PK/PD Perspective
Session 2: Software Validation
- Mould: Introduction to Workshop: Session II Content and Terms
- Gobburu: Population Analysis Software Validation: Good Practices
- Fiedler-Kelly: Example Documentation of Population Software Validation Efforts
2004 Scientific Meeting Presentations
- Booth: "Population Pharmacokinetic Modeling and Simulation-Derived Dosing of Intravenous Busulfan in Pediatric Patients"
- Gopalakrishnon: "A Pharmacokinetic-Pharmacodynamic Model for Insulin to Guide Optimal Drug Delivery"
- Jadhav: "Mixed Effects Model Qualification Using Predictive Check"
- Duan: "Population Pharmacokinetics in Assessing Drug-Drug Interactions: Consideration During Regulatory Review"
- Guzy: "Application of the Monte Carlo Parametric Expectation Maximization (MCPEM) Algorithm for Analyzing Population Pharmacokinetic/Pharmacodynamic (PK/PD) Data"
- Li: "Impact of Mis-specified Residual Model on Parameter Estimates in Population Pharmacokinetic Analysis"
- Nedelman: "Diagnostics for Confounding in a PK/PD Model"
- Madabushi: "Mixed Effects Modeling of Sparse Data: A Comparison of Three Software Packages"
- Tornoe: "Stochastic Differential Equations in NONMEM: A Diagnostic Tool for Pinpointing Model Deficiencies"
- Lee: "Population Pharmacokinetics of Troxacitabine"
- Population Models for Disease Progress and Drug Action (1999)
- Bayesian Approaches For Estimating Population PK Parameters In Pediatric Patients Given Prior Information From Adults